Monday, May 1, 2023

< + > Dutch Ministry Of Health Will Not Reimburse Gilead’s Breast Cancer Drug, Trodelvy

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.

at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

< + > What's behind EHR-induced clinician burnout? And how to solve it?

When evaluating electronic health record systems to minimize documentation burden, usability is always the big challenge, says one informati...